Dublin, July 29, 2022 (GLOBE NEWSWIRE) – The “Global Checkpoint Inhibitor Market Report 2022: By Drug, By Application, By End Users” Report added to ResearchAndMarkets.com Show.
The major players in the checkpoint inhibitor market are AstraZeneca PLC, Bristol-Myers Squibb Company, Merck & Co. , Inc. , Roche Holding AG, Pfizer, Incyte Corporation, Novartis AG, and NewLink Genetics Corporation.
The global checkpoint inhibitors market is expected to grow from $19.86 billion in 2021 to $23.93 billion in 2022 at a compound annual growth rate (CAGR) of 20.5%. The market is expected to reach $46.27 billion in 2026 with a compound annual growth rate of 17.9%.
The checkpoint inhibitors market consists of sales of immune checkpoint inhibitor drugs and related services by entities (organizations, individual dealers, and partnerships) that produce checkpoint inhibitors for cancer treatment. A checkpoint inhibitor is a medication that blocks proteins that prevent the body’s immune system from killing cancer cells. One of the types of cells in the immune system that fight cancer cells are T cells. T cells contain proteins that turn on the immune response and other proteins that turn it off.
These are called checkpoints. Some checkpoints help T cells become active while others help T cells shut down. When cancer cells produce high levels of proteins, the blocked checkpoints restrict immune responses from being robust and sometimes prevent T cells from killing cancer cells. When checkpoints are blocked by a checkpoint inhibitor from binding to partner proteins, this allows T cells to kill cancer cells.
The main types of drugs in checkpoint inhibitors are PD-1 inhibitors, PD-L1 inhibitors, CTLA-4, T-cell chimeric antigen receptor and others. PD-1 and PD-L1 inhibitors are anticancer checkpoint inhibitors that block the action of the immune checkpoint proteins PD-1 and PDL1 at the cell surface. It is used in lung cancer, kidney cancer, leukemia, bladder cancer, skin cancer, etc. and implemented in various sectors such as hospital pharmacies, retail pharmacies and online pharmacies.
North America is the largest region in the checkpoint inhibitor market in 2021. The Middle East is expected to be the fastest growing region in the forecast period. The regions covered in this report are Asia Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East and Africa.
The rise in the number of cancer cases worldwide is likely to contribute to the growth of the checkpoint inhibitors market during the forecast period. According to the American Cancer Society, there were 1.7 million new cases and 0.6 million cancer deaths in 2019 in the United States. The four most common types of cancers worldwide are lung, prostate, bowel and female breast cancer, accounting for 43% of all new cancer cases. Checkpoint inhibitors that target checkpoints are very useful as cancer treatments. Therefore, the rising incidence of cancer globally is expected to increase the demand for the checkpoint inhibitors market.
The high cost of checkpoint inhibitor cancer treatment is expected to limit the checkpoint inhibitor market. Pressure to contain costs and prove value is widespread. Political uncertainty and ongoing economic pressures in many countries raise questions about the sustainability of public healthcare financing. In less affluent countries, the lack of cost-effective treatments for cancer has affected the health conditions of the population and reduced life expectancy.
For example, a course of venous checkpoint inhibitors costs about $150,000 to $250,000, which is very expensive, especially for countries without public insurance. Therefore, the high cost of checkpoint inhibitor cancer treatment is expected to limit the checkpoint inhibitor market.
Major companies in the checkpoint inhibitor market are forming partnerships or collaborations to develop advanced technologies such as bifunctional fusion protein or Y-trap. Most cancer patients do not respond to immune checkpoint inhibitors.
To make immunotherapies more effective, a group of researchers has developed a bifunctional fusion protein, or Y-trap. This drug is created by incorporating a receptor for a protein called TGF-beta that targets a checkpoint protein such as PD-L1 or CTLA-4. Y-Trap targets both the checkpoint inhibitor and TGF-beta and gives a more effective way to prevent immunosuppression and the destruction of cancer cells.
Merck, a prominent science and technology group, and GSK, a global research-based healthcare company, have announced that they have entered into a global strategic partnership to create and commercialize M7824 (bintrafusp alfa). M7824 is a bifunctional fusion protein immunotherapy, which is currently under clinical investigation, including potential enrollment trials, for various hard-to-treat cancers.
This includes a phase II study investigating M7824 compared to pembrolizumab as first-line therapy in patients with PD-L1-expressing advanced non-small cell lung cancer (NSCLC). In another case, in June 2020, Targovax, a Norway-based biotechnology company developing immunostimulants to target solid tumors, entered into a collaboration with Leidos’ Explorations in Global Health (ExGloH) division to evaluate the potential for use of ONCOS, the drug Targovax. Clinical program for oncolytic adenoviruses, as a vector encoding the MicrotideT checkpoint inhibitor peptides.
In June 2020, Targovax, a Norway-based biotechnology company, entered into a collaboration with the Explorations Division in Global Health (ExGloH) at Leidos to evaluate the possibility of using ONCOS, the Targovax clinical oncolytic adenovirus program, as a vector encoding microtide-checkpoint inhibitor peptides.
Explorations in Global Health (ExGloH) at Leidos has created a special group of microbially-derived peptides called MicrotideTM that act as immune checkpoint inhibitors. Leidos is a US-based company that deals with defense, aviation, information technology, and biomedical research.
Main topics covered:
1. Executive Summary
2. Characteristics of the checkpoint retardant market
3. Checkpoint inhibitors market trends and strategies
4. Impact of COVID-19 on checkpoint inhibitors
5. Inspection retardant market size and growth
5.1 Global Historic Checkpoint Inhibitor Market, 2016-2021, USD Billion
5.1.1. market drivers
5.1.2. Market Restrictions
5.2 Global checkpoint inhibitor market forecast, 2021-2026F, 2031F, billion
5.2.1. market drivers
5.2.2. market restrictions
6. Checkpoint Retardant Market Segmentation
6.1 Global Checkpoint Inhibitor Market, Segmentation by Pharmaceuticals, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $1 Billion
- PD-1 . inhibitors
- PD-L1 . Inhibitors
- chimeric antigen receptor T cell
6.2 Global Checkpoint Inhibitor Market Segmentation by Application, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $1 Billion
- Lung Cancer
- kidney cancer
- blood cancer
- Bladder Cancer
- skin cancer
6.3 Global Checkpoint Inhibitor Market, Segmentation by End Users, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $1 Billion
- Hospital pharmacies
- Retail pharmacies
- Internet pharmacies
7. Regional and Country Checkpoint Inhibitor Market Analysis
7.1. Global Checkpoint Inhibitor Market, Segmented by Region, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, USD Billion
7.2 Global Checkpoint Inhibitor Market, Segmented by Country, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, USD Billion
- AstraZeneca plc.
- Bristol-Myers Squibb Company
- Merck & Co
- Roche Holdings AG
- Pfizer Inc
- yte company
- Novartis AG
- NewLink Genetics
- Seattle genetics
- Celldex Treatments
- GlaxoSmithKline Corporation.
- Innate Pharma SA
- Ono Pharmaceutical Co., Ltd.
- Juno Therapeutics
- Kite Pharma
- Eli Lilly and Company (ARMO Biosciences)
- Fortress Biotechnology
- Cure Tech
- Sorrento treatments
For more information about this report visit https://www.researchandmarkets.com/r/86jpt8